Abiding no more

Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus partnership revenues. Now with a more mature story to tell, the company last week tapped VCs for a $20 million series A round to advance its first internal program.